United States

Back to map

Showing 91-100 of 325 grants

Title Institution Researcher Program Duration Total Award Amount
In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy Trustees of Columbia University in the City of New York Remi Creusot Cures 01-August-2022 to 31-July-2025 $1,049,996.66
Low level engraftment of modified HSCs for continuous and omnipresent autoantigen exposure as requirements to establish tolerance Trustees of Columbia University in the City of New York Remi Creusot Cures 01-June-2024 to 31-January-2026 $188,704.16
Improving pig islet transplant efficacy in a preclinical baboon diabetes model with induced immune tolerance to the xenografts Trustees of Columbia University in the City of New York Megan Sykes Cures 01-June-2024 to 31-May-2026 $599,999.94
Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes Trustees of Columbia University in the City of New York Camillo Bechi Genzano Cures 01-March-2025 to 29-February-2028 $256,285.00
Development of Low Cost, High Precision Nano Pumps for Insulin Delivery Torramics Inc. Sergey Gimelshein Improving Lives 01-March-2023 to 31-August-2026 $1,493,212.43
GABP regulation of human beta cell proliferation The University of Texas Health Science Center at Houston Richard Cox Cures 01-September-2024 to 31-August-2026 $200,000.00
The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system The University of North Carolina at Chapel Hill Koji Sode Improving Lives 01-October-2022 to 30-September-2026 $799,999.96
Role of β-cell Golgi dysfunction in Type 1 diabetes pathogenesis The University of Iowa Samuel Stephens Cures 01-June-2024 to 31-May-2027 $750,000.00
Engineered Nanoparticles for Beta Cell-Targeted Therapeutics The University of Chicago Raghavendra Mirmira Cures 01-April-2023 to 31-March-2026 $897,822.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2024 to 31-January-2026 $250,000.00